Skip to content

Study · Animal study (in vivo) · rat · 2013

4 results

LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats.

Liu Z, Ren C, Jones W, Chen P, Seminara SB, Chan YM, Smith NF, Covey JM, Wang J, Chan KK

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences4 Mar 2013Cited by 18 (Europe PMC)

PMID23524040 (opens in a new tab)PMCIDPMC3955120 (opens in a new tab)DOI10.1016/j.jchromb.2013.02.027 (opens in a new tab)PepBankPUB-23524040
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, kisspeptin‑10 was detected at low ng/mL in the first minutes after an intravenous bolus, was eliminated rapidly and was undetectable at 30 min.

    In plain wordsIn rats, kisspeptin‑10 given by injection into a vein was cleared fast and could not be detected after 30 minutes.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicablePlasma kisspeptin-10 time course after i.v. bolus
    Study

    ratn: not reported in source

    Rat
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.0 mg/kg · intravenous bolusAs given in this study (rat).

    Measurements

    Time to undetectable plasma level
    30 min
    after 1.0 mg/kg i.v. bolus

    Source sentences

    Summary
    Pharmacokinetic study in rats showed that low ng/mL kisspeptin-10 was detected in the first few minutes, and eliminated rapidly and became undetectable 30 min after intravenous (i.v.) bolus administration of 1.0 mg/kg kisspeptin-10.

Studies that did not test the peptide alone3

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 02LabNot a test of Kisspeptin-10 aloneOther designOther

    Kisspeptin‑10 degraded rapidly, with decomposition half-lives of 6.8 min at 4 °C, 2.9 min at 25 °C and 1.7 min at 37 °C.

    In plain wordsIn lab tests, kisspeptin‑10 broke down quickly, and faster at higher temperatures.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableStability (decomposition half-life) of kisspeptin-10
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Decomposition half-life
    6.8 min
    4 °C
    Decomposition half-life
    2.9 min
    25 °C
    Decomposition half-life
    1.7 min
    37 °C

    Source sentences

    Summary
    With this method, stability studies demonstrated that kisspeptin-10 degraded rapidly with decomposition half-lives of 6.8 min, 2.9 min and 1.7 min at 4 °C, 25 °C, and 37 °C, respectively.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  2. 03LabNot a test of Kisspeptin-10 aloneOther designOther

    An LC-MS/MS assay quantified kisspeptin‑10 in rat plasma with a lower limit of quantitation of 0.5 ng/mL.

    In plain wordsIn lab tests, a new assay measured kisspeptin‑10 in rat plasma down to 0.5 ng/mL.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicableLC-MS/MS assay performance in rat plasma
    Study

    ratn: not reported in source

    Rat plasma
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Lower limit of quantitation
    0.5 ng/mL
    rat plasma assay
    Within-day CV
    5.2 to 15.4%
    rat plasma assay
    Between-day CV
    1.3 to 14.2%
    rat plasma assay
    Within-day accuracy
    98 to 114%
    rat plasma assay
    Between-day accuracy
    99 to 105%
    rat plasma assay

    Source sentences

    Summary
    The lower limit of quantitation (LLOQ) was 0.5 ng/mL, the within-day and between-day coefficient of variations (CVs) ranged from 5.2 to 15.4% and 1.3 to 14.2%, and the accuracy values ranged from 98 to 114% and 99 to 105%, respectively.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  3. 04LabNot a test of Kisspeptin-10 aloneOther designOther

    The principal decomposition product of kisspeptin‑10 was the N-terminal tyrosine deleted kisspeptin‑10.

    In plain wordsIn lab tests, kisspeptin‑10 mainly broke down by losing its first amino acid, tyrosine.

    Peptide
    Kisspeptin-10
    Outcome
    Not applicablePrincipal decomposition product
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The principal decomposition product was characterized as the N-terminal tyrosine deleted kisspeptin-10 (46)NWDSFGLRF-NH2(54).

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    9 Oct 2026, 18:17 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.